Business Wire

Vaccibody Becomes Nykode Therapeutics - a New Name and Identity to Signify a New Phase of Growth and Development

Share

Nykode Therapeutics (formerly Vaccibody*)) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that the Company is changing its name to reflect its exciting development and mark a milestone in our journey of growth and transformation. It acts as a visible symbol of a new phase of opportunity based on collaborations, internationalization, and future ambitions. And it conveys how we are truly starting to realize our vision of being a leading immunotherapy platform company, breaking down the boundaries of conventional drug design to unlock the future of medicine.

The Company’s new name is inspired by its Norwegian roots and links to our platform’s modularity. Nykode translates as ‘new code’, playing on the potential of our technology to generate novel codes and create innovative patient therapies.

Michael Engsig, CEO of Nykode Therapeutics: “Over the last few years, the Company has made significant steps forward. We have reported promising clinical data, continued to grow our pipeline and forged significant partnerships.” Michael Engsig added, “We continue our exciting transformation from a two-asset focused company to a fully-fledged platform biotech company. During the past year, we have increased the number of talented colleagues, made important additions to our senior management team, invested strategically, and expanded internationally. This positive evolution, combined with our future ambitions, inspired the need to revisit our brand.”

Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued, “The challenge of changing our name was to consolidate everything we have achieved to date with our future plans to expand, and combine this into a powerful new brand.” Agnete B. Fredriksen added, “We have shown that we can generate novel molecules by combining multiple different genes or codes to generate new medicines with unique properties. We will build further on this know-how, driven by our guiding purpose to push the boundaries of human advancement by rethinking conventional drug design. We want to express how our platform’s intelligent modular design and tailored hyper targeting may deliver game-changing medicines for patients. This vision aims to create innovative therapies and continues to broaden our reach into multiple therapeutic areas, both with and without our partners. In essence, we believe that our new name, Nykode, uniquely captures our progress and possibilities.”

Read more about the journey and inspiration regarding our new name, logo, and visual identity on our new website, nykode.com.

*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.

About Nykode Therapeutics

Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.

The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact for Nykode Therapeutics AS:

CEO Michael Engsig
Nykode Therapeutics AS
ir@nykode.com

Nykode Therapeutics AS

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yokogawa Acquires PXiSE, a Developer of High-speed Control Software for Grids and Renewable Energy Assets2.12.2021 03:00:00 CET | Press release

Yokogawa Electric Corporation (TOKYO:6841) announces it has acquired all of the outstanding shares of PXiSE Energy Solutions LLC., a San Diego-based developer of software that enables utilities and other grid operators to deliver reliable and stable power by managing renewables and distributed energy resources (DERs) in real time. Through this acquisition, Yokogawa will build on its capabilities in the monitoring and control of power generation facilities and assist customers in the power transmission and distribution sectors to meet their clean energy goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005473/en/ Integration of DERs and grid components through automated grid control (Graphic: Yokogawa Electric Corporation) Renewable energy sources such as wind and solar PV are crucial for reducing greenhouse gas emissions, however the power generated is unpredictable as they are affected by the weather conditions. I

Seoul Semiconductor Supplies SunLike LED, a Natural Light Reproduction Technology, to KOIZUMI's Learning Lighting2.12.2021 01:00:00 CET | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, announced on the 2nd that it supplied SunLike, a natural light LED, to KOIZUMI FURNITECH Technology Corp., a Japanese learning furniture company. KOIZUMI FURNITECH, a company specializing in traditional Japanese learning furniture, is an affiliated company of Koizumi Group, same as Koizumi, a premium lighting company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005018/en/ KOIZUMI desk light (left) and children's room lighting (right) with SunLike technology (Photo: Business Wire) Seoul Semiconductor has been supplying SunLike technology to KOIZUMI lighting company. SunLike technology was already applied to KOIZUMI's children's room lighting and living room lighting in July 2020, and this time it was applied to desk light (ECL-111 and ECL-112) that helps create an optimal learning and reading environment. SunLike technology is the

Applied Risk releases new Operational Technology (OT) Security report, “Architecting the Next Generation for OT Security”2.12.2021 01:00:00 CET | Press release

Applied Risk, a leading global provider of industrial cyber security solutions, is pleased to announce the release of a new report describing current conditions in the Operational Technology (OT) Security realm and offering insight into emerging OT Security Trends. The report, entitled “Architecting the Next Generation for OT Security,” is based on data collected by the Ponemon Institute from more than 1,000 IT and OT Security practitioners (United States and Europe). The research was then complemented by input from Applied Risk’s own engagements and assessments as well as analysis by its subject matter experts (SMEs). The report notes that the sector has been shaped by factors including lower-than-ideal staff levels, the adoption of risk-based and OT-specific standards, and the failure to adopt enabling technologies. It also addresses urgent matters such as questions about ownership of OT Security Leadership, concerns about access management and the promise of new technologies such as

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results2.12.2021 00:30:00 CET | Press release

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced today The Lancet Respiratory Medicine (“Lancet”), an internationally trusted, peer-reviewed source of clinical, public health, and global health knowledge, published positive results from Humanigen’s LIVE-AIR Phase 3 randomized, controlled trial of lenzilumab in hospitalized COVID-19 patients, as well as an independent expert commentary. The Lancet paper concludes “LIVE-AIR showed that lenzilumab treatment of hospitalised patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo.”2 “Publication of LIVE-AIR results in this peer-reviewed medical journal is a major achievement. Our goal was to demonstrate that lenzilumab, a variant-agnostic therapy, could address the unmet

Square, Inc. Changes Name to Block1.12.2021 22:30:00 CET | Press release

Square, Inc. (NYSE: SQ) announced today that it is changing its name to Block. Block will be the name for the company as a corporate entity. The Square name has become synonymous with the company’s Seller business, which provides an integrated ecosystem of commerce solutions, business software, and banking services for sellers, and this move allows the Seller business to own the Square brand it was built for. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201006139/en/ Block logo in white The change to Block acknowledges the company’s growth. Since its start in 2009, the company has added Cash App, TIDAL, and TBD54566975 as businesses, and the name change creates room for further growth. Block is an overarching ecosystem of many businesses united by their purpose of economic empowerment, and serves many people—individuals, artists, fans, developers, and sellers. “We built the Square brand for our Seller business, which is

Bentley Systems Announces the Year in Infrastructure 2021 Founders’ Honorees1.12.2021 22:01:00 CET | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the Year in Infrastructure 2021 Founders’ Honorees. During the 2021 Year in Infrastructure and Going Digital Awards virtual event today, 22 Founders’ Honorees were recognized, representing organizations or individuals whose undertakings contribute notably to infrastructure advancement and/or environmental/social development goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201006051/en/ Bentley Systems Announces the Year in Infrastructure 2021 Founders’ Honorees Bentley Systems founders Keith and Greg Bentley, and Bentley’s Director of ES(D)G Rodrigo Fernandes, reviewed the compelling credentials of 18 Honorees selected from 230 organizations who submitted nominations for the company’s annual Going Digital Awards in Infrastructure program. Chief Acceleration Officer Santanu Das recognized three Honoree organiz

CORRECTING and REPLACING: Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India1.12.2021 18:28:00 CET | Press release

Regulatory News: This replaces the announcement made at 3:15 PM on December 1st due to the following corrections: Last quote was cancelled. Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India A collaboration supported by the EDF Group and based on French complementarity and excellence. Apave, ESI Group and Onet Technologies have formalized, at the WNE (World Nuclear Exhibition) 2021, their collaboration, through the MINS (Make in India Nuclear supply chain Support) alliance, to build a common value proposition in order to respond to the project to create six EPR reactors on the Jaitapur site in western India. Philippe Maillard, CEO of APAVE Group, Emmanuel Leroy, EVP Product, Innovation & Industry Solutions of ESI Group and Alain Gauvin, CEO of ONET Technologies, signed today at WNE 2021, with the participation of Xavier Ursat, Group Senior Executive Vice President, New Nuclear Projects and Engineering, a joint declara